Cytovas is a pioneering life science company that is revolutionizing precision medicine through its unique cell-based informatics platform, CLOUD CYTOMICS™. This innovative platform provides actionable insights on novel cellular markers of disease progression and individual treatment responses, empowering clinicians and drug developers in creating safer, targeted therapies. Founded in 2010 by experts from the University of Pennsylvania, the company has garnered substantial funding from the American Heart Association, the National Institutes of Health, and the University of Pennsylvania, and also has a strategic partnership with Becton Dickinson Biosciences.
Their technology, which efficiently utilizes flow cytometry data, is widely applicable across various therapeutic areas and disease stages, making it an invaluable asset in all phases of drug development. CytoVas collaborates with partners in diverse fields including Cardiovascular Disease, Type 2 Diabetes, Preeclampsia, Alzheimer’s, Acute Myeloid Leukemia, Psoriasis, Rheumatoid Arthritis, and Peripheral Arterial Disease, with future studies planned for Traumatic Brain Injury. The company is currently led by a seasoned management team and a scientific advisory board with a proven track record of success.
The last Venture Round investment in August 14, 2017 was secured from BioAdvance, signifying a strong vote of confidence from the investment community in the company's vision and potential for growth in the precision medicine and biotechnology industries.
